Black box medication list

A black box medication list is a clinical reference of drugs that carry an FDA boxed warning. That warning is the most serious safety alert a prescription label can hold. This template groups those drugs by class, from antidepressants and opioids to anticoagulants and fluoroquinolones, and names the specific warning attached to each.

Prescribers use it as a check before they sign a prescription. Front-desk and nursing staff use it at intake to spot patients already taking a high-risk drug. Below, you’ll find the full list by drug category and how it differs from the ISMP high-alert list. You’ll also find five steps to build it into your workflow.

Key takeaways

A black box medication list collects the drugs that carry an FDA boxed warning, the most serious safety alert on a prescription label.

Antidepressants carry a suicidality warning for patients under 25, and opioids and benzodiazepines carry a shared warning against combined use.

Warfarin’s boxed warning covers bleeding, while apixaban, rivaroxaban and dabigatran warn of clots if stopped early and of spinal or epidural hematoma.

The FDA boxed warning list and the ISMP high-alert list overlap but are not the same, so a practice needs to track both.

Recording each counseling discussion in the patient record supports your own documentation and audit trail.

What is a black box warning?

A black box warning, formally a boxed warning, is the strongest warning the FDA puts on a drug label. The FDA adds one when evidence shows a medication carries a serious or life-threatening risk. The warning sits in a black-bordered box at the top of the prescribing information, where prescribers see it first.

A boxed warning differs from a standard warning in three ways:

1. Regulatory weight: It marks the most serious risk on the label. Some boxed warning drugs also have a separate Risk Evaluation and Mitigation Strategy (REMS) program requiring prescriber training or patient enrollment.
2. Visual prominence: The black border sets it apart from the standard warnings and precautions section, which runs as plain text further down the label.
3. Prescriber accountability: Documenting the counseling conversation is good practice for any boxed warning drug. It becomes a requirement only where a REMS program or a state rule applies.

The FDA keeps the box for risks it judges serious enough to need special attention. A drug can still carry one when its benefit outweighs the risk for the patients who take it.

How the FDA adds a boxed warning

The FDA can require a boxed warning when it approves a drug, or add one later through a safety labeling change. Later additions usually start with post-market data. Clinicians, patients and manufacturers send adverse event reports to the FDA’s MedWatch program, and FDA safety reviewers investigate when a pattern emerges.

The agency may consult an external advisory committee of independent experts, but it doesn’t have to. If the evidence supports a boxed warning, the FDA requires the manufacturer to update the label. The new warning then applies to every prescription going forward.

Boxed warnings change over time. The FDA can add, modify or, rarely, remove one as new evidence emerges. In 2007, for example, it expanded the antidepressant suicidality warning to cover young adults aged 18 to 24.

Black box medication list by drug category

The table below groups the main drug classes that carry FDA boxed warnings. Grouping by class lets staff find a drug quickly during prescribing or intake. The same structure works as one section per class in patient intake software.

Antidepressants and suicidality in younger patients

The antidepressant suicidality warning is the boxed warning most clinicians know. In 2004, the FDA required all antidepressants to carry a boxed warning for increased suicidal thoughts and behavior in children and adolescents. That covers SSRIs like sertraline and paroxetine, SNRIs like venlafaxine and duloxetine, and tricyclics. In 2007, the FDA extended the warning to young adults aged 18 to 24.

What the warning asks of prescribers: Monitor patients closely for worsening mood, new suicidal thoughts or unusual behavior. The risk is highest in the first few months of treatment and after dose changes, so patients and caregivers need to know the signs too. An AI medical scribe can draft the consultation note, so the counseling discussion reaches the record without retyping.

The warning doesn’t mean antidepressants cause suicide. For most adult patients, the benefit outweighs this risk. The FDA still judged the risk large enough that prescribers should screen for it at every review.

Opioids and benzodiazepines: The concurrent use warning

In 2016, the FDA added a boxed warning to both opioid analgesics and benzodiazepines about taking them together. Both are central nervous system depressants, and combined use can cause profound sedation, respiratory depression, coma and death.

Clinical implication: Reserve combined prescribing for patients whose other treatment options are inadequate. A chronic pain patient already on a benzodiazepine for anxiety is a common example. Limit doses and duration to the minimum, record the reasoning, counsel the patient on overdose signs and consider prescribing naloxone.

Both drug classes also affect fitness to drive. For patients who hold a commercial driver’s license, check the DOT medication restrictions list as well.

Fluoroquinolones, anticoagulants and other boxed warning classes

Fluoroquinolone antibiotics such as ciprofloxacin and levofloxacin carry a boxed warning for tendon rupture, peripheral neuropathy and worsening myasthenia gravis. These effects can be permanent, and tendon problems can appear weeks after the course ends. For uncomplicated infections such as acute sinusitis, the FDA advises using them only when no alternative treatment exists.

Anticoagulants carry two different boxed warnings. Warfarin’s warning covers major or fatal bleeding, so patients need regular monitoring and clear advice on the signs of bleeding. Apixaban, rivaroxaban and dabigatran warn of increased thrombotic events if a patient stops them early. They also warn of spinal or epidural hematoma in patients having neuraxial anesthesia or a spinal puncture.

Montelukast (Singulair), an asthma and allergy medication, received a boxed warning in March 2020 for serious neuropsychiatric events. These include suicidal behavior, depression and anxiety. The drug had been on the market for more than 20 years. A boxed warning can arrive at any point in a drug’s life.

High-alert medications vs. black box warning medications: What’s the difference?

High-alert medications and black box warning medications are two separate lists, though they overlap.

Black box medications carry an FDA boxed warning on their label. It’s a regulatory classification based on serious risks found in trials or after launch.

High-alert medications are drugs the Institute for Safe Medication Practices (ISMP) identifies as more likely to cause serious harm when used in error. A high-alert list is a patient safety inventory, not a regulatory label.

Warfarin sits on both lists. A dosing error can cause serious bleeding, and its boxed warning covers that bleeding risk at the correct dose too. Oxycodone also appears on both. Concentrated potassium chloride and injectable insulin are high-alert but carry no boxed warning.

The reverse also happens. Fluoroquinolones, montelukast and antidepressants carry boxed warnings but sit outside ISMP’s high-alert lists, because their main risk is an adverse effect at the correct dose. The chart below sorts these examples into three groups.

Your practice’s medication safety plan should track both lists. Use the FDA boxed warning list to guide counseling and monitoring, and the ISMP high-alert list to prevent prescribing and dosing errors.

What the template is used for

The template does three jobs in a practice:

1. Prescriber reference: A quick lookup when writing a prescription. It shows the warning attached to a drug and the counseling or monitoring it calls for.
2. Intake and consent documentation: A structured checklist staff use at intake. It records that a patient received counseling on boxed warning drugs they take or are about to start.
3. Staff training: A standard document for onboarding nurses, physician assistants and nurse practitioners on the practice’s priority medication alerts.

The format depends on practice size and specialty. A solo prescriber may need only a one-page PDF checklist. A multi-location practice might keep the list beside its e-prescribing software, so prescribers check the warning before they sign.

The downloadable PDF holds the full list by drug category. Add your practice’s logo, prescriber names and local policies, then print it for staff or attach it to your medication safety policy.

How to put the list to work in your practice

Building the list into your workflow takes five steps:

1. Download and customize the template. Adapt it to your practice’s specialties. If you don’t prescribe immunosuppressants, condense that row, and if you treat many patients for depression, expand the antidepressant section. Specialty practices often pair it with a narrower reference, such as an ototoxic medication list.
2. Add it to your intake forms. Put boxed warning questions in the medical history section of your digital forms. For example, ask “Are you currently taking any of the medications on this list?” If the answer is yes, follow with a counseling and acknowledgment section.
3. Train staff on the warnings. Every clinician and staff member who reviews medications should understand each boxed warning and the counseling it calls for. A 30-minute session at a quarterly team meeting covers new and updated warnings.
4. Document counseling in the patient record. When a patient starts or already takes a boxed warning drug, record which warning you discussed and that the patient understood the risks. This builds your own clinical and legal audit trail. For drugs given in the practice, log each dose on a medication administration record too.
5. Review and update quarterly. The FDA adds and updates boxed warnings regularly. Ask one person, usually the practice manager or lead clinician, to check the National Library of Medicine’s DailyMed database (FDA-approved labels) each quarter. Then update the template with any new or changed warnings in your therapeutic areas.

Adding boxed warning checks to your software

Many e-prescribing systems pull label data from a commercial drug database. When a prescriber selects a drug with a boxed warning, the system shows an alert on screen. Where your system does this, the alert replaces a manual check against a printed list.

Where it doesn’t, the template does the same job. Add the list to your intake forms and ask prescribers to record the counseling discussion in the treatment note. Practices that already log policies and audits in compliance management software can file the quarterly list review there too.

Why practices keep a boxed warning list

A boxed warning list protects a practice in three ways:

• Patient safety: Every patient on a high-risk drug gets the counseling and monitoring their warning calls for, which lowers the risk of avoidable harm.
• Documentation: A recorded counseling discussion supports your own documentation and audit trail.
• Liability: A note showing the prescriber reviewed the boxed warning with the patient strengthens the practice’s position if an adverse event occurs.

More practices now build boxed warning questions into their standard digital intake forms. That way, the patient’s answer is already in their record when the consultation starts.

How Pabau keeps medication counseling on record

Many practices still track boxed warning counseling on paper. The printed list sits at the front desk, the patient ticks a box, and someone scans the form into a file days later.

Pabau’s digital forms put your boxed warning questions into the medical history form patients complete before their visit. Their answers save to the patient record, next to their prescriptions and treatment notes.

Prescribers then record the counseling discussion in the treatment note, or let Pabau Scribe, our AI scribe, draft it from the consultation. When an auditor or a colleague asks what the patient was told, the answer is in one file. Book a demo to see how the forms and notes fit your prescribing workflow.

Keep boxed warning counseling on record

Pabau’s digital forms, prescribing and treatment notes keep medication history and counseling records in one patient file, ready when an auditor asks.

Book a demo

Conclusion

A boxed warning list only protects patients if someone checks it at the moment of prescribing and records what was said. Start with the drug classes your prescribers use most. Then put the list where your team already works, whether that’s the intake form, the prescribing screen or the treatment note.

The trade-off is upkeep. The FDA keeps adding and revising boxed warnings, so a list nobody reviews each quarter drifts out of date within a year. Book a demo to see how Pabau keeps medication history, counseling notes and consent forms in one patient record.

Continue your research

Treating commercial drivers? DOT medication restrictions list shows which medications can affect a driver’s medical certification.

Watching for hearing damage? Ototoxic medication list groups drugs linked to hearing and balance loss by class and risk level.

Giving medications in the practice? Medication administration record for nursing tracks every dose given, by whom and when.

Need consent before the first dose? Medication administration form captures the medication order, prescriber authorization and consent in one signed record.

Managing lupus patients on immunosuppressants? SLE medication list tracks each drug’s dose, monitoring schedule and review date.

Frequently asked questions